Pay in 4 interest-free payments of $25.71 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer
is a pyrrolopyrimidine-based
Smiles: CC1=CN=C(C=N1=O)C(O)=O
InChi: InChI=1S/C28H33N5O6/c1-28(2
Formula: C29H26N6
PF-04217903 (methanesulfonate) medil Hydrochloride Acquired C797S Mutation upon TreatmentPF 04217903 is a MET tyrosine kinase inhibitor, is also a n orally bioavailabe, small molecule tyrosine kinase inhibitor of the proto oncogene c Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c Met inhibitor PF 04217903 selectively binds to and inhibits c Met, disrupting the c Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction
US$ 34.99
US$ 24.00
US$ 19.50
US$ 15.00